nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.06.2013 | case report

Lenalidomide induced response in a patient with follicular lymphoma of the skin and an anti-rituximab-antibody

verfasst von: Cathrin Skrabs, Christian Sillaber, Ana-Iris Schiefer, Ingrid Simonitsch-Klupp, Thomas Staudinger, Monique Putman, Werner Rabitsch, Ulrich Jaeger

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Patients with follicular lymphoma ineligible for standard treatment with the anti-CD20 antibody rituximab represent a considerable challenge as they require alternative therapeutic approaches.

Patient and methods

We describe a patient who experienced a severe episode of serum sickness. Antichimeric antibodies against rituximab were verified in an early stage of disease, rendering further use of the drug impossible. After five treatment lines he developed progressive follicular lymphoma with skin involvement, which was treated with lenalidomide monotherapy.

Results

Six cycles of lenalidomide monotherapy (25 mg orally for 21 days, 1 week off) led to a very good partial response rendering the patient eligible for autologous stem cell transplantation. Data on efficacy of lenalidomide in follicular lymphoma are reviewed.

Conclusion

As shown here, single-agent lenalidomide represent a therapeutic option for pretreated patients with follicular lymphoma ineligible for rituximab.

Vorheriger Artikel Durable complete remission after brentuximab vedotin in a patient with relapsed and refractory Hodgkin lymphoma (HL)

Nächster Artikel Biomolecular basis of the role of chronic psychological stress hormone ‘‘glucocorticoid’’ in alteration of cellular immunity during cancer

The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin’s lymphoma. Blood. 1997;89:3909–18.

Salles GA. Clinical features, prognosis and treatment of follicular lymphoma. Hematology Am Soc Hematol Educ Program. 2007;216–25.

Aurora V, Winter JN. Current controversies in follicular lymphoma. Blood Rev. 2006;20:179–200.PubMedCrossRef

Dreyling M, Ghielmini M, Marcus R, et al. ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22 (Suppl 6):vi59–63.PubMedCrossRef

O’Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23:676–84.PubMedCrossRef

Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer. 2010;116:106–14.PubMed

Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s Lymphoma. J Clin Oncol. 2009;27:5404–9.PubMedCrossRef

Rituxan (Rituximab) injection [prescribing information]: San Francisco: Genentech, Inc.; 2011.

DeMonaco NA, Jacobs SA. Serum sickness in a patient with follicular lymphoma after rituximab and radioimmunotherapy with ibritumomab tiuxetan. Clin Nucl Med. 2007;32:933–4.PubMedCrossRef

10.

Disperati P, Hicks LK, Buckstein R. Rituximab-induced serum sickness in a patient with follicular lymphoma. Leuk Lymphoma. 2007;48:1633–5.PubMedCrossRef

11.

Goto S, Goto H, Tanoshima R, et al. Serum sickness with an elevated level of human antichimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura. Int J Hematol. 2009;89:305–9.PubMedCrossRef

12.

Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumor activity of rituximab in vivo. Br J Haematol. 2008;140:36–45.PubMed

13.

Lentzsch S, LeBlanc R, Podar K, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia. 2003;17:41–4.PubMedCrossRef

14.

Fowler N, Hagemeister F, Mclaughlin P, et al. Lenalidomide plus rituximab is a highly effective and well-tolerated biologic therapy in untreated indolent B cell non-Hodgkins lymphoma. Abstract 137, 11th International Conference on Malignant Lymphoma 15–18 June 2011, Lugano (Switzerland), Ann Oncol. 2011;22(Suppl 4):iv128–9.

15.

Dutia M, Deroock I, Reed-Pease C, et al. Lenalidomide plus rituximab leads to a high rate of durable responses in patients with relapsed/refractory indolent non-Hodgkin’s lymphoma. Abstract 306, 11th International Conference on Malignant Lymphoma 15–18 June 2011, Lugano (Switzerland), Ann Oncol. 2011;22(Suppl 4):iv183–9.

16.

Ahmadi T, Chong EA, Gordon A, et al. Phase II trial of lenalidomide—dexamethasone—rituximab in relapsed or refractory indolent B-Cell or mantle cell lymphomas resistant to rituximab. ASH Annual Meeting Abstracts. 2010;116:3962.

17.

Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:4952–7.PubMedCrossRef

18.

Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol. 2011;22:1622–7.PubMedCrossRef

19.

Chanan-Khan A, Miller KC, Lawrence D, et al. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer. 2011;117:2127–35.PubMedCrossRef

Titel: Lenalidomide induced response in a patient with follicular lymphoma of the skin and an anti-rituximab-antibody
verfasst von: Cathrin Skrabs
Christian Sillaber
Ana-Iris Schiefer
Ingrid Simonitsch-Klupp
Thomas Staudinger
Monique Putman
Werner Rabitsch
Ulrich Jaeger
Publikationsdatum: 01.06.2013
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 2/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-013-0089-5

Springer Medizin Österreich

Abstract

Background

Patient and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

The Austrian Competence Network on Mastocytosis (AUCNM): a partner and part of the European ECNM network

New developments in acute graft-versus-host disease

Durable complete remission after brentuximab vedotin in a patient with relapsed and refractory Hodgkin lymphoma (HL)

Single-agent bevacizumab as maintenance therapy in metastatic colorectal cancer: how long do we have to continue?

The role of maintenance therapy in metastatic colorectal cancer

Therapy with JAK 1/2 inhibitors for myelofibrosis

The Austrian Competence Network on Mastocytosis (AUCNM): a partner and part of the European ECNM network 